Diagnostic Dilemma

HOW TO TREAT THIS TB_?


Author:
Question
A 2½ years old boy suffering from steroid resistant nephrotic syndrome on Cyclophosphamide and steroids and on antituberculous therapy {ATT} since past 10 months was referred for further management. His Chest X-Ray showed worsening with bilateral diffuse mid-zone and lower zone haziness. He was thus suspected to have either drug resistant TB or progression of TB due to immunosuppression. He was shifted to Category II treatment regimen and advised bronchoalveolar lavage {BAL} for TB culture which showed no acid fast bacilli {AFB} even after 6 weeks. His ATT was stopped after 8 months therapy. However within a month, he again developed cough and fever. In meantime, he was now on Cyclosporine for his nephrotic syndrome along with steroids and Cyclophosphamide had been omitted. His Chest X-Ray showed left mid zone consolidation and BAL was resent for TB culture. There was AFB on smear {4 bacilli seen} but TB culture did not grow any AFB after 6 weeks.

What antituberculous therapy should be given in this child_?
Expert Opinion :
We have started the child on 2nd ATT consisting of Amikacin, Moxifloxacin, PAS, Ethionamide as he has already received 18 months of 1st line drugs without any response. Since smear was paucibacillary, it is quite likely that TB culture may be negative, but it does not rule out drug resistant TB.
Answer Discussion :
M
maraj ullah khan
bubble
isonhizide
8 years ago
A
abdo dabwan farea
bubble
INH. rifampicine. isoniazid
8 years ago

View More Comments

Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0